These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 37359555)

  • 1. DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy.
    Cifaldi L; Melaiu O; Giovannoni R; Benvenuto M; Focaccetti C; Nardozi D; Barillari G; Bei R
    Front Immunol; 2023; 14():1197053. PubMed ID: 37359555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells
    Focaccetti C; Benvenuto M; Pighi C; Vitelli A; Napolitano F; Cotugno N; Fruci D; Palma P; Rossi P; Bei R; Cifaldi L
    Front Immunol; 2022; 13():886319. PubMed ID: 35967339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
    Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
    Front Immunol; 2020; 11():40. PubMed ID: 32082316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.
    Hu Y; Tian ZG; Zhang C
    Acta Pharmacol Sin; 2018 Feb; 39(2):167-176. PubMed ID: 28880014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
    El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
    Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering Natural Killer Cells for Cancer Immunotherapy.
    Rezvani K; Rouce R; Liu E; Shpall E
    Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNAM-1 Activating Receptor and Its Ligands: How Do Viruses Affect the NK Cell-Mediated Immune Surveillance during the Various Phases of Infection?
    Cifaldi L; Doria M; Cotugno N; Zicari S; Cancrini C; Palma P; Rossi P
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31366013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK cell recognition and killing of melanoma cells is controlled by multiple activating receptor-ligand interactions.
    Morgado S; Sanchez-Correa B; Casado JG; Duran E; Gayoso I; Labella F; Solana R; Tarazona R
    J Innate Immun; 2011; 3(4):365-73. PubMed ID: 21576932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.
    Soldierer M; Bister A; Haist C; Thivakaran A; Cengiz SC; Sendker S; Bartels N; Thomitzek A; Smorra D; Hejazi M; Uhrberg M; Scheckenbach K; Monzel C; Wiek C; Reinhardt D; Niktoreh N; Hanenberg H
    Front Immunol; 2022; 13():847008. PubMed ID: 35464442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.
    Sanchez-Correa B; Valhondo I; Hassouneh F; Lopez-Sejas N; Pera A; Bergua JM; Arcos MJ; Bañas H; Casas-Avilés I; Durán E; Alonso C; Solana R; Tarazona R
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of ligands for NKG2D and DNAM-1 receptors by epithelial ovarian cancer-derived exosomes and its influence on NK cell cytotoxicity.
    Labani-Motlagh A; Israelsson P; Ottander U; Lundin E; Nagaev I; Nagaeva O; Dehlin E; Baranov V; Mincheva-Nilsson L
    Tumour Biol; 2016 Apr; 37(4):5455-66. PubMed ID: 26563374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer.
    Obajdin J; Davies DM; Maher J
    Clin Exp Immunol; 2020 Oct; 202(1):11-27. PubMed ID: 32544282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo.
    Lakshmikanth T; Burke S; Ali TH; Kimpfler S; Ursini F; Ruggeri L; Capanni M; Umansky V; Paschen A; Sucker A; Pende D; Groh V; Biassoni R; Höglund P; Kato M; Shibuya K; Schadendorf D; Anichini A; Ferrone S; Velardi A; Kärre K; Shibuya A; Carbone E; Colucci F
    J Clin Invest; 2009 May; 119(5):1251-63. PubMed ID: 19349689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
    Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
    J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.
    Bollino D; Webb TJ
    Transl Res; 2017 Sep; 187():32-43. PubMed ID: 28651074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis.
    Pende D; Bottino C; Castriconi R; Cantoni C; Marcenaro S; Rivera P; Spaggiari GM; Dondero A; Carnemolla B; Reymond N; Mingari MC; Lopez M; Moretta L; Moretta A
    Mol Immunol; 2005 Feb; 42(4):463-9. PubMed ID: 15607800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.